VeriRef Gold® Cod. 16203



customer code:	•••••	• •							GENETICS
PATIENT INFORMATION							Req	uired fields are	e marked with an asterisk (*
*Last name:			*Name:				*6	Birth date:d	d/mm/yyyy
Patient Id.:	*Weight	* Height (cm):							
Address:									
Country: ZIP code:									
BLOOD SAMPLE									
*Date of draw: .dd/mm/yyyy *Time of draw:									
OBSTETRIC HISTORY									
Number of previous deliveries:				of abortions	oortions:				
Date of last birth/abortion or miscar	riage (mon	th/year):	m/yyyy	History of pre	egnan	ncies wit	:h chromoso	mal abnormali	ties or genetic diseases:
Number of previous anomalous preg	nancies: .								
REASON FOR REFERRAL									
☐ First trimester biochemical screening	ng 🗆 Adv	vanced mater	nal age 🗆	Ultrasound find	dings	suggest	ive of chromo	osomal abnorn	nalities Anxiety
☐ Early pregnancy loss ☐ Recurren									,
CURRENT PREGNANCY									
*Gestational age (weeks/days): Method to determine gestational age:									
IVF PREGNANCY: ☐ Yes	/F PREGNANCY: ☐ Yes If IVF, own eggs: ☐ Yes If egg donation, indicate donator's age:								
□ No			□ No	date of eggs' collection: dd/mm/yyyy					
ULTRASOUND INFORMATION									
Date of last ultrasound: dd/mm/aaaa Gestational age by ultrasound (Weeks/days):									
Fetal measurements: Normal	Fetus small	er than gestati	ional age 🗆	Fetus bigger tha	an ges	stational	age		
Morphological study: ☐ Normal ☐ Undone ☐ with abnormalities (specify:)									
SCREENING PREVIO DE TRISOMÍA 2	1								
☐ Yes Test type: ☐ TN + T1st trimester biochemical test ☐ 2nd trimester biochemical test ☐ No									
☐ 1st trimester biochemical test ☐ Combined test: 1st and 2nd trimester Family history of genetic disease									
☐ 2nd trimester ultrasound markers									
☐ Only TN 1st T (or other ultrasound markers) Carrier of a genetic disease									
ORDERING HEALTH CARE PROFESSION	ONAI INFO	ORMATION /	(Reporting A	ddress)					
RDERING HEALTH CARE PROFESSIONAL INFORMATION (Reporting Address) *Last name: *First name:				Email:					
Institution:						Fax:			
Address:			ZIP code:				City: Country:		Country:
I herewith confirm the correctness	of the ab	ove given in	formation.						
		/ /							

Signature of ordering health care professional



TEST INFORMATION AND CONSENT FORM

Required fields are marked with an asterisk (*)



Test limitations

- 1. Although the latest research data indicate that the test is highly accurate, with a detection rate of trisomy 21 close to 100% and a false positive rate of less than 1%, this test can not be considered diagnostic. It should only be considered as a very efficient screening test. Therefore, an abnormal result must always be confirmed by an invasive prenatal test, and a normal result can not exclude with total certainty an affected fetus due to these pathologies. This is due to several limitations of the current methodology.
- 2. This test has a number of limitations that prevent it from being used in cases of: mother with any of the changes to be analyzed, very early pregnancy (<10SG), fetal mosaicism of trisomies, presence of microduplications, chromosomal alteration in regions that were not analysed.
- 3. If the pregnant mother has received an allogeneic blood transfusion, transplant or stem cell therapy, there is a possibility of non-interpretable results due to the presence of exogenous DNA.
- 4. This test analyzes all microdeletions of the fetal genome >7Mb.

ı	- f-			C		
ı	Into	rm	ea	LOI	nsent	

- 1. I fully understand the indication of the test, the objective, its characteristics and potential risks of this test. My doctor, Dr . *....., has answered all my questions about it.
- 2. I fully understand the limitations of this test, in particular that the detection rate of the changes studied is close but is NOT 100%. In cases of twin pregnancies, only trisomies of chromosomes 13, 18 and 21 and presence of the Y chromosome can be reported.
- 3. I confirm all the provided information about me is true and correct.
- 4. I understand that test result will be ready in about two weeks from when the lab receives the sample, but it could be ready in less time.
- 5. I was informed that it may be necessary to re-provide blood (<1% of cases).
- 6. I understand that the results are reference values and do not represent an element of clinical diagnosis. The results obtained should be considered in the context together with other clinical criteria, so it is recommended that these results be communicated in medical consultation.
- 7. I agree to provide information about my pregnancy, especially if my future baby is affected by some kind of genetic disease. I understand and authorize my doctor to contact me to know this information.
- 8. I give my consent for the use of clinical data by my laboratory for auditing, quality assurance and research purposes, provided that my person remains anonymous and not identifiable, and all the information I have provided is excluded from any publication. I can exercise my rights and revoke that consent at any time by contacting my laboratory.
- 9. About personal data: According to Spanish Law 41/2002, regulating Patient Autonomy, and Spanish Law 3/2018 on the Protection of Personal Data, the test applicant must have the written consent of the patient (and/or their legal representatives) to carry out this test and the treatment of their personal data. The information collected in this form will be incorporated into a confidential automated file under the terms established in Spanish Law 3/2018, with the purpose of carrying out the genetic study requested here. The patient, or their legal representatives, may at any time exercise their rights of access, rectification, deletion, limitation, opposition and portability by requesting it through his/her laboratory.

* Patient's name and last name:	* Patient's signature:	* Place and date:
* Healthcare professional prescriber name:	* Healthcare professional prescriber signature:	* Place and date:

REG-402-01 Page 2/2